Anticancer and Anti-Inflammatory Activity of Probiotic Lactococcus lactis NK34

J Microbiol Biotechnol. 2015 Oct;25(10):1697-701. doi: 10.4014/jmb.1503.03033.


The anticancer and anti-inflammatory activities of probiotic Lactococcus lactis NK34 were demonstrated. Treatment of cancer cells such as SK-MES-1, DLD-1, HT-29, LoVo, AGS, and MCF-7 cells with 10(6) CFU/well of L. lactis NK34 resulted in strong inhibition of proliferation (>77% cytotoxicity, p < 0.05). The anti-inflammatory activity of L. lactis NK34 was also demonstrated in lipopolysaccharide-induced RAW 264.7 cells, where the production of nitric oxide and proinflammatory cytokines (tumor necrosis factor-α, interleukin-18, and cyclooxygenase-2) was reduced. These results suggest that L. lactis NK34 could be used as a probiotic microorganism to inhibit the proliferation of cancer cells and production of proinflammatory cytokines.

Keywords: Lactococcus lactis; Probiotic; anti-inflammatory activity; anticancer activity; cytokine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / metabolism*
  • Antineoplastic Agents / metabolism*
  • Cell Line
  • Cell Proliferation
  • Coculture Techniques
  • Cytokines / metabolism
  • Humans
  • Lactococcus lactis / metabolism*
  • Macrophages / drug effects
  • Macrophages / immunology
  • Mice
  • Nitric Oxide / metabolism
  • Probiotics / metabolism*


  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Cytokines
  • Nitric Oxide